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Summary
Objective: To examine the potential of insulin, in a sustained delivery system, as a treatment for arthritis.
Design: The effect of insulin on matrix synthesis, matrix breakdown, and nitric oxide production in primary cartilage explants was examined.
The activity of insulin on diseased cartilage from Dunkin Hartley guinea pigs, diabetic mice, and osteoarthritic patients was measured. The
specificity of insulin stimulation was compared to that of IGF-I using osteoblasts and fibroblasts. Finally, the stability of insulin in a biologically
relevant system was tested, and a slow-release formulation of insulin was developed and characterized.
Results: In articular cartilage explants, insulin stimulated proteoglycan (PG) synthesis, inhibited PG release and nitric oxide production, and
overcame the detrimental effects of interleukin 1 (IL-1). The mechanism whereby insulin decreased matrix breakdown was through inhibition
of aggrecanase activity. Insulin was active on cartilage at concentrations at which insulin does not cross-react with insulin-like growth factor
I (IGF-I) receptors nor stimulate proliferation of other cells types. The response of cartilage to insulin did not diminish with age or disease.
Insulin stimulated matrix synthesis in osteoarthritic cartilage and local treatment with insulin overcame endogenous suppression of matrix
synthesis in diabetic cartilage. Poly-lactic-coglycolic acid (PLGA) was found to be an effective carrier for delivery of insulin, and PLGA-Insulin
was active on articular cartilage in vitro and in vivo.
Conclusions: As the incidence of arthritis increases with the aging population, an effective therapy to induce repair of cartilage is needed.
Based on its biological activities, insulin appears to be an attractive protein therapeutic candidate. Maximum insulin effectiveness may
require a sustained delivery system. © 2002 OsteoArthritis Research Society International. Published by Elsevier Science Ltd. All rights
reserved.
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Osteoarthritis (OA) is characterized by loss of cartilage
matrix molecules i.e. proteoglycans (PG) and collagens.
Because of the limited replicative capacity of mature
chondrocytes and the avascular nature of cartilage, mature
cartilage has little ability to effectively repair itself1. Growth
factors modulate chondrocyte proliferation, differentiation,
migration, and matrix turnover2. Treatment with growth
factors alone, or as part of a device, could be used to
promote in vivo repair cartilage or to promote expansion of
cells ex vivo. Several secreted peptides, including mem-
bers of the insulin-like growth factor (IGF), bone morpho-
genetic protein (BMP), and transforming growth factor beta
(TGF-) families, have the potential to induce cartilage
repair1,2.
IGF-I is of particular interest, since insufficiency of IGF-I
may have an etiologic role in the development of osteo-
arthritis2,3. More specifically, serum IGF-I concentrations
can be lower in osteoarthritic patients relative to controls3.
In addition, chondrocyte responsiveness to IGF-I
decreases with age and disease, a phenomenon which
may be due to increased production of IGF binding pro-
teins (IGF-BPs)3–8. Thus, decreased availability of, and692responsiveness to, IGF-1 may contribute to loss of homeo-
stasis and cartilage degeneration with increasing age and
disease3–8.
Insulin can stimulate the growth of a number of cell
types9,10, including chondrocytes from hypophysectomized
rats11,12. Most of the earliest studies with insulin were
performed in whole animals, organs, or tissues11–14. In
chondrocytes derived from chick embryo sternal cartilage,
insulin stimulates mucopolysaccharide synthesis, amino
acid uptake, and promotes a positive nitrogen balance15.
Similarly, insulin increases proteoglycan synthesis in rat
tumor cells derived from a Swarm rat chondrosarcoma16.
Levels of insulin as high as 10 g/ml were used in many of
these studies. At such high concentrations, insulin binds to,
and activates, the IGF-1 receptor, thus mimicking the
effects of IGF-I itself17. The observed physiological effects
could therefore be the result of IGF-I receptor signaling.
We have tested the effect of insulin on articular cartilage
at concentrations at which activation of IGF-I receptors
does not occur17. At these low concentrations (≤10 nM),
insulin decreased matrix breakdown by inhibiting aggreca-
nase activity. Insulin also increased matrix synthesis,
inhibited nitric oxide production, and blocked the detri-
mental effects of IL-1 on articular cartilage. Since insulin
was not stable in articular cartilage cultures, we created
and characterized a slow-release formulation of insulin. We
show that our slow-release formulation was efficacious
in vitro and in vivo. Finally, our data suggest that a
decrease in insulin is associated with defective matrix
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REAGENTS
Recombinant human interleukin 1alpha, IL-1, pur-
chased from R&D systems (Minneapolis, MN), was re-
suspended in phoshate buffered saline (PBS) 0.1% and
bovine serum albumin (BSA) prior to use. Recombinant
human IGF-I and recombinant human des-(1-3)-IGF-I were
made at Genentech. Recombinant human insulin was from
Intergen (Purchase, New York).ANIMALS
Mice and male Dunkin Hartley guinea pigs were
obtained from Charles River Laboratories (Wilmington,
MA). All animals were maintained and treated according to
guidelines for care and use of animals by the Institutional
Animal Care and Use Committee (IACUC).CHONDROCYTE PREPARATION
Articular cartilage was aseptically dissected from the
metacarpo-phalangeal joints of 4–6-month-old female pigs
(University of California Davis, Davis, CA). Cartilage frag-
ments were digested in 0.05% trypsin in serum-free Ham’s
F12 (F12) for 25 min at 37°C. Cartilage was further
digested in 0.3% collagenase B (Boehringer Mannheim.
Mannheim, Germany) in F12 media for 30 min at 37°C.
Cartilage was then digested overnight in 0.06% colla-
genase B in F12+10% fetal bovine serum (FBS). Cells
were filtered (70 m nylon filter) and seeded at 8×106 in
150 cm2 flasks in F12 medium+10% FBS.CULTURING OF CHONDROCYTES
Chondrocytes (prepared as described above) were
grown in 150 cm2 flasks and then were plated on microtiter
plates (Falcon microtest 96, flat bottom) at a density of
80,000 cells per well in F12 with antibiotics (10 g/ml
gentamicin, 250 ng/ml amphotericin B, 100 U/ml penicillin/
100 g/ml streptomycin) and 10% FBS. 24 h after plating
cells were treated with various factors in serum-free media
and cultured for 5 days.MTT ASSAY
Dimethylthiazol-diphenyltetrazolium bromide, MTT18,
cell proliferation kit was used as per manufacturer’s
protocol (Boehringer Mannheim).MEASUREMENT OF PROTEOGLYCANS
To measure proteoglycans, we used a dimethylmethyl-
ene blue (DMMB) assay19, a well-accepted method to
measure the amount of proteoglycans in cartilage cul-
tures20. As a standard, chondroitin sulfate was used (0.0 to
5.0 g) from shark cartilage (Sigma, St Louis, MO).ARTICULAR CARTILAGE EXPLANTS
Articular cartilage was aseptically dissected from the
metacarpo-phalangeal joints of 4–6-month-old female pigs,
18–24-month-old cows (Harris Ranch, Selma, CA), or the
femorotibial joint of Dunkin Hartley guinea pigs (1–2, 6, or
11 months old). Cartilage was pooled, minced, washed and
cultured in bulk for at least 24 h in Explant Media, i.e.
serum free low glucose 50:50 DMEM:F12 media with 0.1%
BSA, 100 U/ml penicilin, 100 g/ml streptomycin, 2 mM
L-glutamine, 1× GHT, 0.1 mM MEM sodium pyruvate,
20 g/ml gentamicin (Invitrogen, Carlsbad, CA), 1.25 mg/l
amphotericin B, 10 g/ml transferrin and 5 g/ml vitamin E.
Approximately 50 mg (for porcine and bovine cartilage) or
30 mg (for guinea pig cartilage) of tissue was aliquoted into
micronics tubes (Costar, Acton, MA) and incubated for at
least 24 h in above media before changing to media without
transferrin and vitamin E. Test proteins were then added.
Media was harvested and changed at various time points
(0, 24, 48, 72 h). For human articular cartilage, tissue was
dissected, minced and weighed the same day and test
proteins were added the following day. Human cartilage
samples from OA patients (54–78 years old) undergoing
knee joint replacement because of advanced disease were
obtained from CHTN (Cooperative Human Tissue Network,
Cleveland, Ohio).MEASUREMENT OF PROTEOGLYCAN SYNTHESIS IN ARTICULAR
CARTILAGE EXPLANTS
At 48 h, 35S-sodium sulfate (ICN Radiochemicals, Irvine,
CA) was added to cartilage explants (10 Ci/ml). After an
overnight incubation at 37°C, media were used to measure
nitric oxide or proteoglycan content. Cartilage pieces were
washed two times using explant media. 900 L (750 L for
human articular cartilage) digestion buffer containing
10 mM EDTA, 0.1 M sodium phosphate and 1 mg/ml pro-
teinase K (Invitrogen) was added to each tube and incu-
bated overnight in a 50°C water bath. Samples of digest
were assayed for proteoglycan content. 600 L of digest
was mixed with 600 L of 10% w/v cetylpyridinium chloride,
CPC (Sigma). Samples were spun at 1000 g for 15 min.
Supernatant was removed, and 500 L formic acid (Sigma)
was added to samples to dissolve precipitates. Solubilized
pellets were transferred to scintillation vials containing
10 ml scintillation fluid (ICN), and samples were counted. In
tests for IGF-I sensitivity, human articular cartilage explant
cultures were labeled when test proteins were added.
Explant cultures were washed and digested the following
day.WESTERN BLOT ANALYSIS
CPC was added to culture media from bovine explants
treated for 3 days to a final concentration of 1% (w/v).
Precipitated proteoglycans and proteoglycan fragments
were collected by centrifugation. Pellets were washed with
1% (w/v) CPC then dissolved in isopropanol/water (3:2,
v/v). Two volumes of ethanol saturated with potassium
acetate were added at 4°C, and proteoglycan samples
(now as their potassium salts) were collected by centri-
fugation. Pellets were then washed twice with ethanol, then
with ether, and air dried. Proteoglycan samples were
dissolved at 10 mg/ml in 0.1 M Tris/acetate, pH 7.0,
containing 10 mM EDTA, 10 mM iodoacetamide, 5 mMsynthesis, and that insulin may have advantages over other
therapeutic growth factors, such as IGF-I.
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0.24 unit/ml keratanase I (endo -galactosidase, Sigma),
0.1 unit/40 mg Keratanase II and 0.12 unit/ml chondroiti-
nase ABC and incubated at 37°C overnight. Digestion was
terminated by addition of SDS/PAGE sample buffer and
boiling for 3 minutes. Samples were run on 4–12% Tris-
glycine SDS/PAGE gradient gels and electroblotted to
nitrocellulose membranes (Novex, San Diego, CA), which
were probed with 1:1000 dilution of antibodies recognizing
either the aggrecanase generated N-terminal neopeptide
ARGSV (antibody #71) or the MMP-generated N-terminal
IGD neoepitope FFGVG (antibody #247)21. Subsequently,
membranes were incubated with sheep antirabbit Ig horse-
radish peroxidase conjugate (Amersham Biosciences,
Piscataway, NJ) and aggrecan catabolites were visualized
by incubation with the SuperSignal West Pico Chemilumi-
nescent Substrate (Pierce) for 5 min and then exposed.NITRIC OXIDE ASSAY
Using a fluorometric assay based on the Griess reac-
tion22, we measured nitrate, a stable end-product of nitric
oxide metabolism which is an appropriate indicator of NO
synthesis in vitro23, in the media of cultured explants or
chondrocytes.EFFECT OF INSULIN ON CARTILAGE FROM DIABETIC MICE
Eight-week-old female CD-1 mice were injected with 30
or 50 mg/kg streptozotocin (STZ) for 5 consecutive days.
Blood glucose levels were measured using a glucose meter
(One-Touch, Lifescan, Buckinghamshire, UK). Two months
later, patellae were harvested and incubated in Explant
Media (see above), in the absence or presence of insulin
(100 nM), for 2 days, and labeled with 35S-sulfate (final
concentration 30 Ci/ml) overnight. A patella assay was
then performed.PATELLA ASSAY
Patellae assays were performed as previously
described24,25. Briefly, following labeling with 35S-sulfate
(30 Ci/ml), samples were washed three times with phos-
phate buffered saline (PBS). Samples were then fixed
overnight in 10% formalin followed by decalcification of the
underlying bone in 5% formic acid. Cartilage was dissected
away from the underlying bone, placed in 500 l of a tissue
and gel solubilizer (Solvable) and incubated at 60°C for
1.5 h. Scintillation fluid designed for concentrated alkaline
and salt solutions (HIONIC-fluor, Perkin Elmer, Boston,
MA) was added (10 ml) to each tube and mixed thoroughly.
35S uptake was then measured using a scintillation counter.EFFECT OF INSULIN OR IGF-I ON FIBROBLASTS AND OSTEOBLASTS
Mouse fibroblast cell line NIH3T3 and human osteoblast
cell line MG-63 were purchased from ATCC (Manassas,
VA). In 96-well plates, NIH3T3 cells were seeded at a
concentration of 5000/well, and MG63 cells were seeded at
a concentration of 1000/well in high glucose DMEM (HGD-
MEM) containing 10% FBS, 2 mM L-glutamine, and 100 U/
ml penicillin, 100 g/ml streptomycin. 24 (NIH3T3) or 72
(MG63) hours after seeding, cells were changed into serumfree media and test proteins were added. At day 3 (MG63)
or day 6 (NIH3T3), cells were analysed by an MTT assay.STABILITY OF INSULIN
Insulin (10 nM) was incubated at 37°C and 5% CO2 in
explant media alone or with articular cartilage explants.
Media was harvested at various timepoints and tested for
activity in the insulin kinase receptor activation assay.INSULIN KINASE RECEPTOR ACTIVATION (KIRA) ASSAY17
For cell stimulation, Chinese hamster ovary (CHO) cells
transfected with the human insulin receptor were cultured
overnight in 96-well plates (Falcon 1270). Cells were then
treated with sample in PS/20 medium with 0.5% BSA for
15 min at 37°C. Cells were lysed by the addition of Lysis
Buffer (150 mM NaCl, 50 mM HEPES, 0.5% Triton-X 100,
1 mM AEBSF, 10 000 IU/ml Aprotinin, 0.05 mM Leupeptin,
and 2 mM sodium orthovanidate). Levels of insulin receptor
autophosphorylation in cell lysates were then assessed by
enzyme-linked immuno-sorbent assay, ELISA. For ELISA
analysis, 96-well plates (Nunc Maxisorp) were coated
with capture antibody (antiinsulin receptor, clone 83-7,
LabVision, Inc., Fremont, CA) at 2 g/ml in PBS and then
blocked with 0.5% BSA in PBS. Plates were washed three
times with wash buffer (PBS with 0.05% Tween-20). Cell
lysates (from above) were diluted 1:5 in lysis buffer and
incubated on the prepared ELISA plates for 2 h. After
washing six times, plates were incubated for 2 h with
biotinylated detection antibody (anti-phosphotyrosine,
clone 4G10, Upstate Biotechnology, Inc., Waltham, MA) at
0.1 g/ml in Assay Buffer (PBS with 0.5% BSA, 0.05%
Tween-20 and 5 mM EDTA). Plates were washed six times
and incubated for 1 h with Streptavidin/HRP (Amdex,
Denmark) in Assay Buffer. Plates were washed six times
and incubated with tetramethyl benzidine substrate solution
(Kirkegaard and Perry). After sufficient color development,
the reaction was quenched with 1.0 N H3PO4, and the
absorbance at 450 nm was read.SLOW-RELEASE FORMULATIONS OF INSULIN
Microsphere formulations: the Zn:human insulin (HI)
hexamer ratio was altered—formulation I–(2:1) and formu-
lation II–(4:1)—while the protein loading remained constant
(approximately 5.0%) in the microsphere formulations pre-
pared. The molar ratio of lactide to glycolide in all polymers
was kept constant at 50:50. All microsphere formulations
were prepared using D,L- poly lactic-coglycolic acid
(PLGA) obtained from Boehringer Ingelheim (Ingelheim,
Germany; RG502H; 0.2 dl/g, 8 kD). Recombinant human
insulin (Eli Lilly, Indianapolis, IN) was encapsulated into
PLGA microspheres using a cryogenic, non-aqueous
process26.
The above human insulin formulations were first spray-
freeze-dried in preparation for insertion into the micro-
spheres. To do this, the above formulations were atomized
through an ultrasonic nozzle (Sono-Tek, Milton NY) into
liquid nitrogen, followed by lyophilization as previously
described26. For example, the dried Zn-HI powder
(100 mg) was added to 5.8 ml of a 0.17 mg/ml solution
of the D,L-PLGA (above) in ethylacetate solvent and
homogenized for 2 minutes at 8000 rpm with a shear
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suspension of Zn-HI and polymer. The polymer and Zn-HI
suspension was sprayed through a sonicating nozzle
(Sono-Tek, Milton NY) into a vessel containing 300 ml of
frozen ethanol. The vessel was then placed in a −70°C
freezer whereupon the frozen ethanol melted and micro-
pheres slowly hardened as the ethylacetate solvent was
extracted by the ethanol. After 3 days, hardened micro-
spheres were harvested by filtration (20 m screen) then
dried under nitrogen gas for 4 days and finally sieved
(60 m screen).PROTEIN ANALYSIS
Encapsulated human insulin was recovered from the
microspheres by dissolving in 1.0 N sodium hydroxide
(NaOH) and analyzed by UV absorbances.CHROMATOGRAPHY
To determine the physical integrity of insulin recovered
from the compositions, Size exclusion (SEC) and reverse-
phase chromatography (RPC) procedures were performed
as previously described27. Briefly, SEC was performed on a
Zorbax® Column with phosphate buffer as the mobile
phase. Human insulin was detected by UV absorption at
214 nm. Reverse-phase chromatography was carried out
on a C-18 reversed-phase column using sulfate buffer with
acetonitrile as the mobile phase at 40°C, human insulin
was detected by UV absorption at 214 nm as previously
described27.RELEASE OF INSULIN IN BUFFER
Twenty mg of each human insulin microsphere formu-
lation was placed in 500 l of release buffer (10 mMHistidine, 10 mM NaCl, 0.02% Polysorbate 20, 0.02%
NaN3, pH 7.2) and incubated at 37°C to evaluate the in
vitro release profile for human insulin microsphere formu-
lations. The entire release medium was replaced at each
sampling interval with resulting release samples stored at
4°C prior to analysis.RELEASE OF INSULIN IN SYNOVIAL FLUID
Synovial fluid was harvested from 7–8-week-old male
Sprague-Dawley rats and diluted 1:2 with phosphate
buffered saline (PBS). The entire release medium was
replaced at each sampling interval with resulting samples
stored at 4°C prior to analysis.EFFECT OF PLGA-INSULIN MICROSPHERES ON PROTEOGLYCAN
RELEASE AND SYNTHESIS
Explants were treated with PLGA-Ins microsphere
resuspended in (Explant Media) on day 0, and media was
harvested and replaced (without microspheres) on subse-
quent days. Other samples in explant media (see above)
were treated with fresh insulin (10 nM) at each media
change (i.e. at 0, 24, and 48 h timepoints). Proteoglycan
breakdown and synthesis were measured as described
above.Fig. 1. Proteoglycan synthesis in primary articular chondrocytes. Porcine articular chondrocytes were treated with various concentrations of
insulin (0.1, 1, 10, 100 nM), either alone or with IL-1 (1 ng/ml) in serum-free media. Media was analysed for proteoglycan content using a
DMMB assay. Data represents the average of four independent samples±S.E.M. **=P<0.01 for insulin treated vs control. ##=P<0.01 vs IL-1
alone.INTRA-ARTICULAR INJECTIONS
PLGA-Ins microspheres were resuspended in 500 l of
buffer (0.1% hyaluronic acid in PBS), and 3 l of this
solution was injected intraarticularly into mouse joints. As
a control, 3 l of buffer was injected into the contra-
lateral knee. Three days later, proteoglycan synthesis was
measured in a patella assay.
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Differences between experimental groups were tested
using a Student’s t-test. P values were adjusted using a
Bonferroni correction for multiple comparisons28. As indi-
cated in figures, *=P-adjusted <0.05, and **=P-adjusted
<0.01.ResultsINSULIN INCREASES PROTEOGLYCAN SYNTHESIS IN PORCINE
PRIMARY CHONDROCYTES
Primary porcine chondrocytes in explant media were
treated with insulin at 0.1, 1, 10, 100 nM in the absence
or presence of IL-1 at 1 ng/ml. Insulin increased
proteoglycan (PG) synthesis in basal and IL-1 treated
cultures in a dose-dependent manner (Fig. 1). Enhance-
ment of synthesis was more pronounced under basal
conditions. For example, insulin at 100 nM increased basal
PG synthesis by 140% but increased that of IL-1 treated
cultures by only 70%. Insulin, at a concentration as low as
0.1 nM, was able to overcome the inhibitory effect of IL-1
on PG synthesis (Fig. 1). The ability of insulin to counteractthe detrimental effects of IL-1 makes insulin an attractive
candidate for the treatment of arthritis in which high levels
of IL-1 are implicated in disease progression.Fig. 2. Matrix turnover in porcine articular cartilage. Porcine articular cartilage explants were treated with Insulin (10 nM) or (a), (b) fetal
bovine serum (10%) alone or (c), (d) with IL-1 (1 ng/ml) and the amount of (a), (c) proteoglycan release and (b), (d) proteoglycan synthesis
was examined. Data represents the average of five independent samples±S.E.M. **=P<0.01 for insulin or serum treated vs control and
##=P<0.01 vs IL-1 alone.EFFECT OF INSULIN ON ARTICULAR CARTILAGE EXPLANTS
In porcine articular cartilage explants, insulin at 10 nM
decreased matrix breakdown by 30% [Fig. 2(a)] and
increased matrix synthesis by 240% [Fig. 2(b)] with efficacy
equivalent to that of 10% serum [Fig. 2(a),(b)]. In addition,
insulin suppressed IL-1 induced catabolism [Fig. 2(c)] and
overcame the inhibitory effect of IL-1 on proteoglycan
synthesis [Fig. 2(d)] at concentrations as low as 0.33 nM
(data not shown).
To better understand the mechanism whereby insulin
reduced cartilage matrix breakdown, we analyzed proteo-
glycan degradation products released from articular
cartilage explants. Western blot analysis of aggrecan
fragments released into the media from treated tissues was
performed using antibodies which recognize either the new
NH2 terminal ARG generated by aggrecanase, or the
new NH2 terminal FFG generated by MMP activity21. No
MMP-generated fragments were found in explants
treated with IL-1, unlike the MMP-generated neo-epitopes
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p-aminophenylmercuric acetate, APMA29 (data not shown).
In contrast, aggrecanase generated fragments were found
in basal and IL-1 treated samples29 (Fig. 3). The high
molecular mass band at ∼230 kDa could be formed by
initial cleavage at the Glu373-Ala374, and additional cleav-
age in the C terminus at other sites could create the smaller
products. Insulin decreased basal and IL-1 induced produc-
tion of these aggrecanase generated termini (Fig. 3). Thus,
insulin inhibited aggrecanase activity, present in articular
cartilage explants under serum-free conditions and in the
presence of IL-1.
In addition to its ability to decrease matrix breakdown
and increase matrix synthesis, insulin also inhibited nitric
oxide (NO) production by as much as 40% (at 100 nM) in
basal or IL-1- (1 ng/ml) treated articular cartilage explants
(Fig. 4). This effect was seen at concentrations of insulin as
low as 1 nM and was also observed in IGF-I treated
explants (Fig. 4).Fig. 3. Western blot analysis of aggrecan fragments generated in articular cartilage explants. Bovine articular cartilage was incubated for
72 h in the presence of insulin (10 nM), IL-1 (50 or 10 ng/ml) or insulin (10 nM) plus IL-1 (10 ng/ml) and aggrecan fragments in the culture
media were analyzed by probing a Western blot with an antibody which recognizes the new NH2 terminal (ARG)21 produced by aggrecanase
cleavage (diagram).EFFECT OF INSULIN ON GUINEA-PIG ARTICULAR CARTILAGE
Two factors known to affect cartilage matrix metabolism
are age and disease. Not only does the rate of biosynthesisand the ability to repair tissue decrease with age, but
disease is also associated with a decrease in growth factor
sensitivity. More specifically, the response of arthritic carti-
lage to IGF-I is significantly blunted relative to age-matched
controls5,7,8,30,31.
Because the highly reproducible pattern of cartilage
breakdown in Dunkin Hartley (DH) guinea pigs is similar to
that seen in the human disorder, the DH guinea pig is a
well-accepted animal model for OA32–36. For this reason,
we tested the effect of insulin on cartilage from guinea pigs
at various ages, and thus various stages of degeneration.
Insulin increased proteoglycan (PG) synthesis to approxi-
mately the same extent (∼two-fold) in articular cartilage
from 1–2 months (90%) [Fig. 5(a)], 6 months (110%)
[Fig. 5(b)], or 11 months (130%) [Fig. 5(c)] old DH guinea-
pigs. Thus, insulin is anabolic for articular cartilage from DH
guinea pigs at various ages and stages of disease.
Besides increasing proteoglycan synthesis, insulin also
decreased matrix breakdown, as shown by a decrease in
the amount of proteoglycans in the media of insulin-treated
explants [Fig. 5(d)]. Most importantly, the insulin-induced
decrease in breakdown and increase in synthesis resulted
in a significant net gain in the amount of proteoglycans
remaining in insulin-treated cartilage, even in tissue from
11-month-old animals treated for only 3 days [Fig. 5(d)].
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To better understand the effects of diabetes on cartilage
matrix metabolism and to test the effects of insulin in
another model of diseased, potentially growth-factor resist-
ant cartilage, we measured matrix synthesis in articular
cartilage from streptozotocin (STZ)-induced diabetic mice
cultured alone or in the presence of insulin. Articular
cartilage from severely diabetic, STZ-treated mice had
lower basal levels of proteoglycan synthesis than untreated
control mice (data not shown) or mildly diabetic, STZ-
treated mice (Fig. 6). This decrease in synthesis could be
due to the fact that STZ-treatment results in low serum
insulin levels due to destruction of pancreatic cells which
produce insulin37. Insulin treatment increased matrix syn-
thesis (approximately two-fold) in cartilage from mild and
severely diabetic mice (Fig. 6). In contrast, IGF-I is not able
to increase proteoglycan synthesis in cartilage from STZ-
treated animals38. Therefore, diseased tissue may not be
equally responsive to anabolic factors, and insulin may
prove to be more effective than IGF-I in promoting skeletal
repair in such individuals.EFFECT OF INSULIN ON OTHER CELL TYPES
Our data suggest that local delivery of insulin into the
joint could be a useful therapeutic for OA. Because several
tissues are present within the joint, we tested the effect of
insulin on two cell types present in and around cartilage.
Bone cells and fibroblasts were treated with insulin or IGF-I
at various concentrations, and cell proliferation was
measured (Fig. 7). At lower concentrations (0.1 and 1 nM),
insulin did not stimulate proliferation of either cell type,
unlike IGF-I which stimulated growth of both bone cells and
fibroblasts (Fig. 7). Thus, local treatment of a joint with
insulin at low concentrations might allow for specific stimu-
lation of cartilage without expansion of bone or synovial
fibroblast cell populations.Fig. 4. NO production by articular cartilage explants. Porcine articular cartilage was treated with insulin (100, 10, 1, 0.5 nM) or IGF (100, 10,
1 ng/ml), either (a) alone or (b) with IL-1 (1 ng/ml), and the amount of nitric oxide in the culture media was measured. Data represents the
average of five independent samples±S.E.M. *=P<0.05 and **=P<0.01 vs control (0).EFFECT OF INSULIN ON HUMAN ARTICULAR CARTILAGE EXPLANTS
In an effort to compare the activities of IGF-I and insulin
on human tissue, we tested their effect on cartilage matrix
synthesis in articular cartilage explants harvested from
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thesis was stimulated by both IGF-I and insulin in tissue
from a number of patients, insulin was more active than
IGF-I in 20% of the tested articular cartilage samples from
osteoarthritic individuals undergoing joint replacement
(Fig. 8). Des-(1-3)-IGF-I (desIGF), a naturally occurring
variant of IGF-I missing the 3 amino-terminal amino acids,
lacks affinity for IGF-BPs, but retains ability to activate IGF-I
receptors39. Like Insulin, desIGF induced cartilage matrix
synthesis in these IGF-I resistant tissues (Fig. 8).Fig. 5. Effect of insulin on guinea pig articular cartilage. Articular cartilage was harvested from male Dunkin Hartley guinea pigs at different
ages and cultured as explants in serum-free media without (−) or with insulin (Insulin) at 100 nM. Proteoglycan synthesis was measured in
articular cartilage from guinea pigs which were (a) 1–2 (b) 6 or (c) 11 months of age. (d) Articular cartilage from 11-month-old guinea pigs
was treated with insulin (100 nM) (Ins) for 3 days, and proteoglycan release (Media) and proteoglycans remaining in the cartilage (Tissue)
were measured. Data represents the average of five independent samples±S.E.M. *=P<0.05 and **=P<0.01 vs control (−).CREATION OF A SLOW-RELEASE INSULIN
In order to establish criteria for a therapeutic formulation
of insulin, we tested the stability of recombinant insulin
protein. While insulin remained fairly stable when culturedin media at 37°C, addition of articular cartilage led to a
dramatic decrease in the amount of active insulin present
(Fig. 9). In fact, within 24 h after incubation with cartilage,
the amount of active insulin had decreased by ∼20%, and
by 4 days of culture, the amount of active insulin had
decreased by 70% (Fig. 9).
As a first step to increase insulin’s stability, the effect of
several carriers on articular cartilage was tested. When
cartilage explants were divitalized by a brief incubation in
base, proteoglycan release and incorporation of 35S-sulfate
was completely prevented (data not shown). Thus, our
assays are measuring cell-mediated processes. Of the
carriers tested, two substantially reduced cartilage matrix
synthesis and were therefore excluded as possible carriers
(data not shown). We therefore created a slow-release
formulation comprised of microencapsulation of a spray-
freeze-dried insulin into a matrix of poly-lactic-coglycolic
700 L. Cai et al.: Insulin and cartilageacid (PLGA), a material which has been used in other
skeletal applications.Fig. 6. Effect of insulin on cartilage from diabetic mice. Patellae
were harvested from STZ treated mice which had mild (mean
glucose= 213 mg/dcl) (Mild) or severe (mean glucose=576 mg/
dcl) (Severe) diabetes, and matrix synthesis was measured after
culturing in media alone (−) or with 100 nM insulin (Ins). *=P<0.05
and **=P<0.01 vs untreated (−) patellae from mildly diabetic mice,
and ##=P<0.01 vs untreated (−) patellae from severely diabetic
mice.Fig. 7. Effect of Insulin or IGF-I on osteoblast and fibroblast proliferation. (a) MG63 cells (osteoblasts) and (b) NIH3T3 cells (fibroblasts) were
treated with Insulin or IGF-I at various concentrations (0.1, 1, 10, 100 nM), and cell proliferation was measured using an MTT assay. Data
represents the average of 6 independent samples±S.E.M.SIZE, PROTEIN LOAD AND PHYSICAL INTEGRITY OF THE
SLOW-RELEASE FORMULATION
The amount of insulin in the slow-release composition
was determined by chemical analysis, and the physical
integrity of insulin recovered from the compositions was
determined by size-exclusion (SEC) and reverse phase
chromatography (RPC). We created two formulations with
different insulin to zinc ratios, as defined as moles insulin
hexamer/moles of zinc. Formulation I had a ratio of 1:2,
while formulation II had a ratio of 1:4. The mean particle
diameter distribution of the microspheres was measured on
a Malvern Masterisizer X and was found to be 30.2±12 nm
for Formulation I and 36.6±11 nM for Formulation II. Pro-
tein loading of Formulation I and Formulation II was found
to be 5.56% and 5.59%, respectively. Analysis of insulin
integrity indicated no significant differences between the
protein before and after encapsulation as determined by an
insulin kinase receptor activation assay (KIRA) (data not
shown).
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In order to determine the amount of insulin released,
insulin-loaded microspheres were incubated in a histidine
buffer or synovial fluid. Samples taken at several timepoints
were assayed using an insulin KIRA because of its high
sensitivity. An initial burst of release (at day 1) of protein
was seen in both buffer and synovial fluid (Fig. 10). The
release profiles of insulin indicated a biphasic release
pattern with almost 40% of the total loaded protein released
in the first 24 h, followed by a lag phase (<1% daily
release) and a second release phase (2–5% daily release)
over the next 15 days at which point 89% of the total
protein loaded had been released [Fig. 10(a)]. Addition of
zinc to the formulation appeared to decrease both the
magnitude of the initial burst as well as slow the subse-
quent release [Fig. 10(a)]. After incubation in synovial fluid
for 3 days, microspheres from formulation II continued
to release active insulin with a concentration of >5 M
[Fig. 10(b)]. Thus, active insulin was released from loadedmicrospheres, and the formulation process did not seem to
be detrimental to protein quality.BIOLOGICAL ACTIVITY OF INSULIN AFTER RELEASE FROM THE
SLOW-RELEASE MATRIX
To determine the effect a slow-release system might
have in vivo, insulin-loaded microspheres were tested
on articular cartilage explants. PLGA-Insulin (PLGA-Ins)
microspheres were added to articular cartilage explants on
day 0, and media was harvested and changed (without
adding more PLGA-Ins microspheres) every day for 3 days.
As a control, other samples were treated with fresh insulin
(10 nM) at each media change (i.e. at 0, 24, and 48 h
timepoints). Activity was determined by measuring proteo-
glycan breakdown and synthesis and nitric oxide produc-
tion. Treatment with PLGA-Ins microspheres decreased
matrix breakdown by 30% [Fig. 11(a)] and increased matrix
synthesis by 130% [Fig. 11(b)]. In addition, the ability of
IL-1 to induce matrix breakdown [Fig. 11(a)] and inhibit
matrix synthesis [Fig. 11(b)] was prevented by co-treatment
with PLGA-Ins. Finally, PLGA-Ins inhibited both basal and
IL-1 induced nitric oxide production by 20% and 30%,
respectively [Fig. 11(c)].Fig. 8. Response of human OA tissue to IGF-I or Insulin. Human OA tissue (from a 70-year-old female with severe osteoarthritis) was treated
with IGF-I (80 ng/ml), desIGF38 (80 ng/ml) and insulin (equimolar concentration), and proteoglycan synthesis was measured. Data
represents the average of nine independent samples±S.E.M. *=P<0.05, **=P<0.01 vs control.Fig. 9. Stability of insulin in media alone or with articular cartilage.
Insulin (10 nM) was added to porcine articular cartilage explants
(With tissue) or incubated in serum-free explant media alone
(Alone) at 37°C and 5% CO2. For 4 days, media was tested for
insulin activity by an insulin kinase receptor activation (KIRA)
assay.IN VIVO EFFECT OF SLOW-RELEASE INSULIN FORMULATION ON
MATRIX SYNTHESIS
Data from explant cultures can be useful predictors of
in vivo effects on articular cartilage. However, within the
joint several types of tissue are present, and proteins can
be rapidly cleared from the synovial fluid. Therefore, to
determine whether or not insulin released from PLGA-Ins
microspheres had an effect on cartilage in vivo, we injected
mouse knee joints with PLGA-Ins microspheres and
measured proteoglycan synthesis in vitro [Fig. 12(a)].
Three days after injection of PLGA-Ins into mouse
knee joints, matrix synthesis was significantly (P<0.05)
stimulated relative to the contralateral, buffer-injected joint
[Fig. 12(b)]. Even under conditions in which insulin could be
702 L. Cai et al.: Insulin and cartilagecleared from the synovial fluid and/or taken up by surround-
ing tissues and cells, articular cartilage had an anabolic
response to the insulin released by the PLGA-Ins micro-
spheres. The increase observed herein may underestimate
the beneficial effects of insulin on cartilage matrix in vivo,
since the ability of insulin to decrease cartilage breakdown
(see Fig. 2) would not have been detected by this assay
and thus would not be included in the calculated benefit.
The decrease in breakdown induced by insulin would
further increase the amount of matrix retained in insulin-
treated knee joints. Rather surprisingly, no gross adverse
effects were seen upon intra-articular injection of very high
doses (30 g) of insulin once/day for 3 days.
Taken together, our results indicate that insulin remains
active after release from microspheres and suggest thatPLGA-Ins might be useful as a local, slow-release delivery
system for the treatment of cartilage defects.Fig. 10. Release of human insulin from PLGA microspheres. (A) PLGA encapsulated microspheres were placed in 10 mM histidine, 10 mM
NaCl, 0.02% polysorbate 20, 0.02% NaN3, pH 7.2 and incubated at 37°C. Release medium was replaced at each sampling interval, and
samples were analyzed for bioactive insulin in an insulin kinase receptor activation (KIRA) assay. (B) Release of insulin in synovial fluid.
PLGA-insulin was incubated in synovial fluid harvested from rat knee joints, and duplicate samples were taken daily—day 1 (1a, 1b), day 2
(2a, 2b), and day 3 (3a, 3b)—and tested by a KIRA assay. As a control, synovial fluid spiked with insulin at 500 nM (Control) was also tested.
Synovial fluid itself had no detectable insulin activity (data not shown).Discussion
We have shown that insulin had positive effects on
matrix metabolism in isolated chondrocytes and articular
cartilage explants from pigs, cows, and humans. Insulin
stimulated proteoglycan synthesis in isolated primary
articular chondrocytes, which are produced by removal of
the surrounding extracellular matrix, and may thus be
similar to cells found in later stages of cartilage disorders
where the matrix has been depleted. In articular cartilage
Osteoarthritis and Cartilage Vol. 10, No. 9 703Fig. 11. Effect of slow release insulin on articular cartilage explants. Porcine articular cartilage was treated with PLGA-insulin (PLGAIns) and
PLGA-insulin-Zn (PLGAIZn) once (at time 0), in the absence or presence of IL-1 (1 ng/ml) (IL-1). Media was changed at 24 h, and 48 h,
without adding additional PLGA-insulin. Samples treated with insulin (10 nM) (Ins) received fresh insulin with the media change at each
timepoint (0, 24 h, 48 h). (A) Proteoglycan release (B) proteoglycan synthesis and (C) nitric oxide production were measured. Data
represents the average of five independent samples±S.E.M. *=P<0.05 and **=P<0.01 for insulin treated vs control (−). #=P<0.05 and
##=P<0.01 vs IL-1 alone.explants, in which cells remain embedded in the tissue
architecture produced in vivo, insulin inhibited matrix break-
down and stimulated matrix synthesis. Our results show
that insulin stimulated matrix synthesis in articular cartilage
from various ages of Dunkin Hartley guinea pigs which
undergo spontaneous cartilage degeneration similar to that
of OA32–36. Thus, insulin has potential as a treatment for
OA at different stages of joint destruction.
Since matrix breakdown is one of the earliest and most
destructive features of arthritis, inhibition of this process
and stimulation of new matrix molecules would be expected
to promote tissue and joint repair in vivo1,2. High levels of
IL-1 are found in arthritic joints, and antagonism of IL-1
function has been shown to reduce the progression of
OA40. Similarly, nitric oxide can have detrimental effects on
chondrocytes as well as other cell types within the joint, and
inhibition of nitric oxide can inhibit progression of arthritis
in animals41. The ability of insulin to counteract thedeleterious effects of IL-1 suggests that insulin could inhibit
the degradation which occurs in arthritic conditions.
While intra-articular injections are generally well-tolerated
by patients and once/week injections of therapeutics are
currently being tested, an ideal drug would be one in which
a limited number of treatments was required. Unfortunately,
human insulin is unstable when stored in neutral sol-
utions at low concentration for extended periods of time42.
Furthermore, insulin has a half-life of about 5 min in the
human body42,43. Because insulin stability was dra-
matically decreased in the presence of articular cartilage,
we developed a stabilized, slow-release formulation of
insulin. A Zn:human insulin complex is believed to result in
a longer-acting formulation of insulin. In fact, histochemical
evidence indicates that human insulin is stored in the
pancreas as a zinc complex42,43. In addition, human insulin
complexed with zinc appears to be more resistant to
aggregation than uncomplexed human insulin42. Finally,
704 L. Cai et al.: Insulin and cartilageinsulin complexed with zinc can have a slower onset and a
longer duration of activity (up to 24 h) in humans relative to
regular insulin42. We created a slow-release poly-lactic-
coglycolic acid (PLGA) insulin formulation which was found
to be efficacious in vitro and in vivo. Addition of more zinc to
our slow-release poly-lactic-coglycolic acid (PLGA) matrix
altered release kinetics.
Patients with diabetes mellitus (DM) have an increased
number of musculoskeletal injuries and disorders relative to
patients without diabetes44,45. In fact, diabetes is one of the
known risk factors for developing arthritis. Changes in
proteoglycans have been found in the intervertebral disc of
diabetic patients, and articular cartilage samples from
patients with DM have compromised structural integ-
rity44,45. The mechanism underlying these changes in
articular cartilage in diabetic patients is not yet known. In
animal models of diabetes, systemic changes in insulin
(in diabetic or hypophysectomized animals) can result in
changes in connective tissues such as skin13,46 and in
aortae47,48. Systemic administration of insulin can at least
partially reverse the defects in connective tissue
metabolism47–49. However, these effects of insulin may be
due to circulating factor(s) induced by insulin and not due to
direct effects of insulin on connective tissues49. We found
that the defect in cartilage matrix synthesis in diabetic mice
could be reversed by transient, local treatment with insulin.
These results suggest that insulin deficiencies can lead to
abnormally low rates of cartilage matrix synthesis. Further-
more, insulin could be an effective treatment for disorders
(other than primary arthritis) in which cartilage tissue has
defects in matrix synthesis and/or breakdown.
The metabolic imbalance in osteoarthritis which favors
matrix breakdown over new matrix synthesis may be due,
at least in part, to insensitivity of chondrocytes to IGF-I
stimulation3–8. While the mechanism underlying this IGF-I
resistance is not known, the elevation of IGF-binding pro-
teins (IGFBPs) in many OA patients may play a role3–8,30.
Consistent with this hypothesis, we found that articular
cartilage from some (20% of the samples tested) of OA
patients undergoing joint replacements responded better to
insulin and IGF variants39, which do not bind IGF-BPs, than
to IGF-I alone. In these patients, treatment with insulin mayprove to be more effective than treatment with other growth
factors such as IGF-I.
The mechanism by which insulin decreases matrix
breakdown appears to be through inhibition of aggreca-
nase activity. Furthermore, given that the doses of insulin
at which we see efficacy (0.1, 1, 10 nM) are below the
concentration necessary to activate IGF-I receptors17, sig-
naling by insulin in cartilage may occur through activation of
insulin receptors. Inhibition of IL-1 activity by insulin may be
through production of IL-1 receptor antagonist (IL1ra),
since many growth factors, including IGF-I, stimulate this
inhibitor40.
In addition to the cartilagenous changes in OA, subchon-
dral bone thickens and bony nodules (osteophytes) are
formed. Given these changes in bony architecture and
volume, treatment with a factor which stimulated further
bone growth would not be optimal. Unlike IGF-I, which
stimulated growth of osteoblasts and fibroblasts, insulin (at
low concentrations) was a poor mitogen for these cells.
Thus, local treatment of insulin within the joint may be able
to selectively target articular cartilage, without altering the
surrounding tissues such as bone and synovium.
Taken together, our results demonstrate that insulin
mitigated loss of matrix molecules and stimulated synthesis
of new molecules to replace those lost. The net effect was
to increase the total amount of proteoglycans. These
effects of insulin were shown in vitro and in vivo. By
increasing the amount of matrix retained in cartilage, insulin
treatment in vivo could lead to maintenance of articular
cartilage matrix, and thus inhibition of subsequent joint
destruction and deformity. As such, insulin when delivered
in a sustained release manner is very attractive as a
possible therapeutic for arthritic patients.Fig. 12. Effect of slow-release insulin on matrix synthesis in vivo. (a) Diagram of the patellae assay. Following intraarticular injection into
mouse knee joints, patellae are harvested, labelled with 35S-sulfate, fixed, decalcified, dissected away from the underlying bone, and
counted. (b) PLGA-insulin (PIns) was injected into the articular space of the femorotibial joint of the hind leg of mice. Buffer (PBS+0.1% BSA)
was injected into the contralateral joint as a control (−). Each line represents a single mouse.References
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